- Home
- NXTC vs FTFT Comparison
NXTC vs FTFT Comparison
Compare NXTC & FTFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- FTFT
- Stock Information
- Founded
- NXTC 2015
- FTFT N/A
- Country
- NXTC United States
- FTFT United States
- Employees
- NXTC N/A
- FTFT N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- FTFT Business Services
- Sector
- NXTC Health Care
- FTFT Consumer Discretionary
- Exchange
- NXTC Nasdaq
- FTFT Nasdaq
- Market Cap
- NXTC 13.0M
- FTFT 11.0M
- IPO Year
- NXTC 2019
- FTFT N/A
- Fundamental
- Price
- NXTC $10.77
- FTFT $2.20
- Analyst Decision
- NXTC Strong Buy
- FTFT
- Analyst Count
- NXTC 2
- FTFT 0
- Target Price
- NXTC $25.50
- FTFT N/A
- AVG Volume (30 Days)
- NXTC 49.2K
- FTFT 132.7K
- Earning Date
- NXTC 11-06-2025
- FTFT 11-18-2025
- Dividend Yield
- NXTC N/A
- FTFT N/A
- EPS Growth
- NXTC N/A
- FTFT N/A
- EPS
- NXTC N/A
- FTFT N/A
- Revenue
- NXTC N/A
- FTFT $2,368,206.00
- Revenue This Year
- NXTC N/A
- FTFT N/A
- Revenue Next Year
- NXTC N/A
- FTFT N/A
- P/E Ratio
- NXTC N/A
- FTFT N/A
- Revenue Growth
- NXTC N/A
- FTFT N/A
- 52 Week Low
- NXTC $2.69
- FTFT $1.01
- 52 Week High
- NXTC $19.20
- FTFT $5.70
- Technical
- Relative Strength Index (RSI)
- NXTC 77.64
- FTFT 50.38
- Support Level
- NXTC $6.23
- FTFT $2.01
- Resistance Level
- NXTC $13.17
- FTFT $2.37
- Average True Range (ATR)
- NXTC 0.91
- FTFT 0.18
- MACD
- NXTC 0.50
- FTFT -0.01
- Stochastic Oscillator
- NXTC 67.51
- FTFT 44.05
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About FTFT Future FinTech Group Inc.
Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.